Click here to view online. Add this email to your safelist.
Roxadustat approved in China for the treatment of anaemia in non-dialysis-dependent patients with chronic kidney disease
22 August 2019
AstraZeneca today announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has received marketing authorisation for roxadustat in China for the treatment of anaemia caused by chronic kidney disease (CKD) in non-dialysis-dependent (NDD) patients.
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
